TY - JOUR T1 - Molecular analysis of several in-house rRT-PCR protocols for SARS-CoV-2 detection in the context of genetic variability of the virus in Colombia JF - medRxiv DO - 10.1101/2020.05.22.20107292 SP - 2020.05.22.20107292 AU - Diego A. Álvarez-Díaz AU - Carlos Franco-Muñoz AU - Katherine Laiton-Donato AU - José A. Usme-Ciro AU - Nicolás D. Franco-Sierra AU - Astrid C. Flórez AU - Sergio Gómez Rangel AU - Luz Dary Rodríguez AU - Juliana Barbosa AU - Erika Ospitia AU - Diana Marcela Walteros AU - Martha Lucia Ospina Martínez AU - Marcela Mercado-Reyes Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/05/26/2020.05.22.20107292.abstract N2 - The COVID-19 pandemic caused by SARS-CoV-2 is a public health problem unprecedented in the recent history of humanity. Different in-house real-time RT-PCR (rRT-PCR) methods for SARS-CoV-2 diagnosis and the appearance of genomes with mutations in primer regions have been reported. Hence, whole-genome data from locally-circulating SARS-CoV-2 strains contribute to the knowledge of its global variability and the development and fine tuning of diagnostic protocols. To describe the genetic variability of Colombian SARS-CoV-2 genomes in hybridization regions of oligonucleotides of the main inhouse methods for SARS-CoV-2 detection, RNA samples with confirmed SARS-CoV-2 molecular diagnosis were processed through next-generation sequencing. Primers/probes sequences from 13 target regions for SARS-CoV-2 detection suggested by 7 institutions and consolidated by WHO during the early stage of the pandemic were aligned with Muscle tool to assess the genetic variability potentially affecting their performance. Finally, the corresponding codon positions at the 3′ end of each primer, the open reading frame inspection was identified for each gene/protein product. Complete SARS-CoV-2 genomes were obtained from 30 COVID-19 cases, representative of the current epidemiology in the country. Mismatches between at least one Colombian sequence and five oligonucleotides targeting the RdRP and N genes were observed. The 3’ end of 4 primers aligned to the third codon position, showed high risk of nucleotide substitution and potential mismatches at this critical position. Genetic variability was detected in Colombian SARS-CoV-2 sequences in some of the primer/probe regions for in-house rRT-PCR diagnostic tests available at WHO COVID-19 technical guidelines; its impact on the performance and rates of false-negative results should be experimentally evaluated. The genomic surveillance of SARS-CoV-2 is highly recommended for the early identification of mutations in critical regions and to issue recommendations on specific diagnostic tests to ensure the coverage of locally-circulating genetic variants.HIGHLIGHTSColombian SARS-CoV-2 sequences displayed genetic variability in some target regions used for COVID-19 diagnosis.Mismatches in critical primer regions could impact their performance and the rate of false negative results.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the National Institute of Health, Bogota D.C., Colombia.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Nasopharyngeal swab samples from patients with suspected SARS-CoV-2 infection were received at the Instituto Nacional de Salud (INS) as part of the virological surveillance of COVID-19 from 11 Colombian departments and the capital district. According to the national law 9/1979, decrees 786/1990 and 2323/2006, the INS is the reference lab and health authority of the national network of laboratories and in cases of public health emergency or those in which scientific research for public health purposes as required, the INS may use the biological material for research purposes, without informed consent, which includes the anonymous disclosure of results. This study was performed in accordance with the ethical standards noted in the 1964 Declaration of Helsinki and its later amendments. The information used for this study comes from secondary sources of data that were previously anonymized and do not represent a risk to the community.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author, upon reasonable request ER -